ArticleJournal for immunotherapy of cancer2026

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.

Ignacio Melero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.